Brief: Bone Therapeutics Cash Balance At End Q1 Was 7.13 Million Euros

Biosenic SA

07/05/2019 06:13

May 7 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * REG-BONE THERAPEUTICS PROVIDES FIRST QUARTER 2019 BUSINESS
UPDATE
    * COMPANY ENDED Q1 OF 2019 WITH A CASH BALANCE OF EUR 7.13
MILLION
    * NET CASH BURN FOR FULL YEAR 2019 IS EXPECTED TO BE IN
RANGE OF
EUR 12-13 MILLION
    * ANTICIPATES HAVING SUFFICIENT CASH TO CARRY OUT ITS
BUSINESS
OBJECTIVES UNTIL END OF 2019, TAKING INTO ACCOUNT EUR 3.75
MILLION TO BE RECEIVED UNDER CONVERTIBLE BOND PROGRAMME
    * IN H2 PLANS TO SUBMIT CLINICAL TRIAL APPLICATION (CTA)
WITH
REGULATORY AUTHORITIES IN EUROPE AND UNITED STATES TO ALLOW
START OF A PHASE II/III CLINICAL TRIAL WITH ALLOB IN PATIENTS
WITH DELAYED-UNION FRACTURES, USING ITS PROPRIETARY, OPTIMISED
PRODUCTION PROCESS
    * IN H2 2019 PLANS TO SUBMIT A CTA WITH REGULATORY
AUTHORITIES IN
EUROPE AND USA FOR PHASE III PROGRAMME WITH JTA-004 IN PATIENTS
WITH KNEE OSTEOARTHRITIS

Source text for Eikon:  ID:nGNE9KSs3t 
Further company coverage:  BOTHE.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))